- Home
- IMRX
as of 12-12-2025 3:44pm EST
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 232.9M | IPO Year: | 2021 |
| Target Price: | $17.20 | AVG Volume (30 days): | 819.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.10 - $10.08 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered IMRX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Immuneering Corporation (IMRX)
Director
Avg Cost/Share
$6.67
Shares
7,500
Total Value
$50,025.00
Owned After
156,766
SEC Form 4
Chief Accounting Officer
Avg Cost/Share
$6.39
Shares
300
Total Value
$1,917.00
Owned After
27,533
SEC Form 4
CHIEF PEOPLE OFFICER
Avg Cost/Share
$6.38
Shares
800
Total Value
$5,103.36
Owned After
23,344
SEC Form 4
CHIEF LEGAL OFFICER, SECRETARY
Avg Cost/Share
$6.83
Shares
1,020
Total Value
$6,966.50
Owned After
4,870
SEC Form 4
Director
Avg Cost/Share
$7.03
Shares
7,500
Total Value
$52,730.25
Owned After
156,766
SEC Form 4
Director
Avg Cost/Share
$7.18
Shares
5,000
Total Value
$35,900.00
Owned After
156,766
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Feinberg Peter | IMRX | Director | Oct 3, 2025 | Buy | $6.67 | 7,500 | $50,025.00 | 156,766 | |
| Morales Mallory | IMRX | Chief Accounting Officer | Oct 1, 2025 | Buy | $6.39 | 300 | $1,917.00 | 27,533 | |
| Neufeld Leah R | IMRX | CHIEF PEOPLE OFFICER | Oct 1, 2025 | Buy | $6.38 | 800 | $5,103.36 | 23,344 | |
| Bookman Michael | IMRX | CHIEF LEGAL OFFICER, SECRETARY | Oct 1, 2025 | Buy | $6.83 | 1,020 | $6,966.50 | 4,870 | |
| Feinberg Peter | IMRX | Director | Sep 30, 2025 | Buy | $7.03 | 7,500 | $52,730.25 | 156,766 | |
| Feinberg Peter | IMRX | Director | Sep 29, 2025 | Buy | $7.18 | 5,000 | $35,900.00 | 156,766 |
Compare IMRX vs Leading Stocks
See how IMRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IMRX Immuneering Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.